source
- Sellas’ Phase 3 REGAL AML Immunotherapy Study Delayed, Forecast to Miss Survival EndpointSellas Life Sciences Group’s experimental immunotherapy galinpepimut‑S (GPS) is being tested in a Phase 3 REGAL trial for patients with acute myeloid leukemia in a second remission. The study has b…
- Researchers sue NIH over grant screening that they say violates First Amendment rightsResearchers have filed a class action lawsuit against the National Institutes of Health, claiming the agency violates their First Amendment rights by searching grant applications for specific words…